Josh Neman

ORCID: 0000-0002-6337-9615
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Brain Metastases and Treatment
  • Glioma Diagnosis and Treatment
  • Cancer, Stress, Anesthesia, and Immune Response
  • Lung Cancer Research Studies
  • Nanoplatforms for cancer theranostics
  • CAR-T cell therapy research
  • Cancer Cells and Metastasis
  • Neurogenesis and neuroplasticity mechanisms
  • Cancer-related cognitive impairment studies
  • Radiopharmaceutical Chemistry and Applications
  • Immunotherapy and Immune Responses
  • Chemical Reactions and Isotopes
  • Neuroscience and Neuropharmacology Research
  • Epigenetics and DNA Methylation
  • Click Chemistry and Applications
  • Cancer, Hypoxia, and Metabolism
  • Lung Cancer Treatments and Mutations
  • Nicotinic Acetylcholine Receptors Study
  • Medical Imaging Techniques and Applications
  • Nanowire Synthesis and Applications
  • Bone Tissue Engineering Materials
  • Radiomics and Machine Learning in Medical Imaging
  • Nanoparticle-Based Drug Delivery
  • MicroRNA in disease regulation
  • Cancer Treatment and Pharmacology

Neurological Surgery
2015-2025

University of Southern California
2016-2025

Southern California University for Professional Studies
2024

Keck Hospital of USC
2024

State Street (United States)
2022-2023

LAC+USC Medical Center
2017-2022

USC Norris Comprehensive Cancer Center
2019-2021

Society for Neuroscience
2021

Keck Graduate Institute
2021

City Of Hope National Medical Center
2010-2018

Significance Breast cancer patients typically develop brain metastases years after their initial diagnosis. During this clinical latency, cells must evolve and adapt to the neural microenvironment colonize. We hypothesized that breast may assume brain-like properties survive in brain. Our results suggest overexpress many variables related γ-aminobutyric acid (GABA) were able proliferate by metabolizing GABA as a biosynthetic energy source. The expression of could be malignant adaptation...

10.1073/pnas.1322098111 article EN Proceedings of the National Academy of Sciences 2014-01-06

Purpose: Metastasis to the brain from breast cancer remains a significant clinical challenge, and may be targeted with CAR-based immunotherapy. CAR design optimization for solid tumors is crucial due absence of truly restricted antigen expression potential safety concerns "on-target off-tumor" activity. Here, we have optimized HER2-CAR T cells treatment metastases, determined optimal second-generation route administration xenograft mouse models metastatic tumors, including multifocal...

10.1158/1078-0432.ccr-17-2041 article EN Clinical Cancer Research 2017-10-24

The Polycomb group (PcG) proteins play a critical role in histone mediated epigenetics which has been implicated the malignant evolution of glioblastoma multiforme (GBM). By systematically interrogating Cancer Genome Atlas (TCGA), we discovered widespread aberrant expression PcG members GBM samples compared to normal brain. most striking differences were upregulation EZH2, PHF19, CBX8 and PHC2 downregulation CBX7, CBX6, EZH1 RYBP. Interestingly, changes CBX6 occurred progressively as...

10.1371/journal.pone.0080970 article EN cc-by PLoS ONE 2013-11-15

In response to recent studies, we investigated an association between perioperative β-blockade and breast cancer metastases. First, a retrospective study examining β-blocker use recurrence metastases was conducted on 1,029 patients who underwent surgery at the City of Hope Cancer Center 2000 2010. We followed clinical examined proliferation, migration, invasion in vitro primary brain-metastatic cells β2-activation inhibition. also vivo metastatic potential propranolol-treated cells. For...

10.3892/or.2016.4710 article EN cc-by-nc-nd Oncology Reports 2016-03-28

Patients with primary breast cancer that is positive for human epidermal growth factor receptor 2 (Her2+) have a high risk of developing metastases in the brain. Despite gains systemic control Her2+ disease using molecular therapies, brain remain recalcitrant to therapeutic discovery. The clinical predilection cells colonize likely relies on paracrine mechanisms. neural niche poses unique selection pressures, and neoplastic utilize microenvironment may survival advantage. Tropomyosin-related...

10.1186/s13058-017-0844-3 article EN cc-by Breast Cancer Research 2017-04-26

Brain metastasis (BrM) is an area of unmet medical need that poses unique therapeutic challenges and heralds a dismal prognosis. The intracranial tumor microenvironment (TME) presents several challenges, including the therapy-resistant blood-brain barrier, immune milieu, distinct intercellular interactions, specific metabolic conditions, are responsible for treatment failures poor clinical outcomes. There complex interplay between malignant cells metastasize to central nervous system (CNS)...

10.1093/noajnl/vdab121 article EN cc-by Neuro-Oncology Advances 2021-11-01

Abstract Background Leptomeningeal dissemination (LMD) occurs when tumor cells interact with choroid plexus epithelium (CPE) to gain access cerebrospinal fluid (CSF) in the brain’s meninges and ventricular system. This disease is particularly devastating for patients due our limited understanding few therapeutic options. The leptomeningeal CSF a nutritionally deprived microenvironment cells. Despite this, LMD survive by taking up metabolizing neurotransmitter GABA from CSF. However, we...

10.1093/neuonc/noaf027 article EN Neuro-Oncology 2025-01-30

Abstract Brain metastases (BrM) arising from solid tumors is an ever increasing and often devastating clinical challenge impacting hundreds of thousands patients annually worldwide. As systemic anticancer therapies, thus survival, improve, risk for central nervous system (CNS) recurrence has increased. Historically, with BrM were excluded trials; however, there been a shift towards inclusion over the past decade. To most effectively design next generation trials BrM, multidisciplinary team...

10.1093/noajnl/vdaf049 article EN cc-by-nc Neuro-Oncology Advances 2025-03-01

Medulloblastoma (MB) is a malignant pediatric brain tumor arising in the cerebellum.Although abnormal GABAergic receptor activation has been described MB, studies have not yet elucidated contribution of receptor-independent GABA metabolism to MB pathogenesis.We find primary tumors globally display decreased expression transaminase (ABAT), protein responsible for metabolism, compared with normal cerebellum.However, less aggressive WNT and SHH subtypes express higher ABAT levels metastatic G3...

10.1016/j.celrep.2021.109302 article EN cc-by Cell Reports 2021-06-01

Intervertebral disc degeneration often requires bony spinal fusion for long-term relief. Current arthrodesis procedures use bone grafts from autogenous bone, allogenic backed or synthetic materials. Autogenous can result in donor site morbidity and pain at the site, while materials have variable effectiveness. Given these limitations, researchers focused on new treatments that will allow safe successful repair regeneration. Mesenchymal stem cells received attention their ability to...

10.2147/btt.s22407 article EN cc-by-nc Biologics 2012-03-01

Cancers that exhibit the Warburg effect may elevate expression of glyoxylase 1 (GLO1) to detoxify toxic glycolytic byproduct methylglyoxal (MG) and inhibit formation pro-apoptotic advanced glycation endproducts (AGEs). Inhibition GLO1 in cancers up-regulate glycolysis has been proposed as a therapeutic targeting strategy, but this approach not evaluated for glioblastoma multiforme (GBM), most aggressive difficult treat malignancy brain. Elevated GBM was established patient tumors cell lines...

10.3390/ijms19020406 article EN International Journal of Molecular Sciences 2018-01-30

Abstract Background The antitumor efficacy of human epidermal growth factor receptor 2 (HER2)-targeted therapies, such as humanized monoclonal antibody trastuzumab (Herceptin®, Roche), in patients with breast-to-brain cancer metastasis is hindered by the low permeability blood-brain barrier (BBB). NEO100 a high-purity version natural monoterpene perillyl alcohol, produced under current good manufacturing practice (cGMP) regulations, that was shown previously to reversibly open BBB rodent...

10.1093/neuonc/noab041 article EN Neuro-Oncology 2021-02-16

Brain metastases (BM) are responsible for neurological decline and poor overall survival. Although the pro-metastatic roles of glial cells, acquisition neuronal attributes in established BM tumors have been described, there no studies that investigate initial interplay between neurons brain-seeking tumor cells. The aim this study was to characterize early tumor-neuron interactions induced CNS-adaptive changes cells prior macro-colonization.Utilizing pure cultures brain-naïve patient-derived...

10.1093/neuonc/noab290 article EN Neuro-Oncology 2021-12-17

Abstract Background Effective control of brain metastasis remains an urgent clinical need due a limited understanding the mechanisms driving it. Although gain neuro-adaptive attributes in breast-to-brain metastases (BBMs) has been described, that govern this neural acclimation and resulting competency are poorly understood. Herein, we define role neural-specific splicing factor Serine/Arginine Repetitive Matrix Protein 4 (SRRM4) regulating microenvironmental adaptation colonization breast...

10.1093/neuonc/noad175 article EN Neuro-Oncology 2023-09-16

Abstract: Gliomas remain one of the most challenging solid organ tumors to treat and are marked clinically by invariable recurrence despite multimodal intervention (surgery, chemotherapy, radiation). This perhaps, is as a consequence failure eradicate tumor cell subpopulation, termed cancer stem cells. Isolating, characterizing, understanding these tumor-initiating cells through cellular molecular markers, along with genetic epigenetic will allow for selective targeting therapeutic agents...

10.2147/btt.s9497 article EN cc-by-nc Biologics 2010-06-01
Coming Soon ...